CoChat

Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study

Open access
Lu, Ching-Hua, Petzold, Axel, Topping, Jo, Allen, Kezia, Macdonald-Wallis, Corrie, Clarke, Jan, Pearce, Neil, Kuhle, Jens, Giovannoni, Gavin, Fratta, Pietro, Sidle, Katie, Fish, Mark, Orrell, Richard, Howard, Robin, Greensmith, Linda, Malaspina, Andrea · 2015 · Journal of Neurology, Neurosurgery & Psychiatry
Cited by 103

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: To investigate the role of longitudinal plasma neurofilament heavy chain protein (NfH) levels as an indicator of clinical progression and survival in amyotrophic lateral sclerosis (ALS). METHODS: A cross-sectional study involving 136 clinically heterogeneous patients with ALS and 104 healthy and neurological controls was extended to include a prospective analysis of 74 of these ALS cases, with samplings at approximately 3-month intervals in a follow-up period of up to 3 years. We analysed the correlation between longitudinal NfH-phosphoform levels and disease progression. Temporal patterns of NfH changes were evaluated using multilevel linear regression. RESULTS: Baseline plasma NfH levels were higher than controls only in patients with ALS with short disease duration to baseline sampling. Compared with controls, fast-progressing patients with ALS, particularly those with a short diagnostic latency and disease duration, had higher plasma NfH levels at an early stage and lower levels closer to end-stage disease. Lower NfH levels between visits were associated with rapid functional deterioration. We also detected antibodies against NfH, NfH aggregates and NfH cleavage products. CONCLUSIONS: Disease progression in ALS involves defined trajectories of plasma NfH levels, reflecting speed of neurological decline and survival. Intervisit plasma NfH changes are also indicative of disease progression. This study confirms that longitudinal measurements of NfH plasma levels are more informative than cross-sectional studies, where the time of sampling may represent a bias in the interpretation of the results. Autoantibodies against NfH aggregates and NfH cleavage products may explain the variable expression of plasma NfH with disease progression. TRAIL REGISTRATION NUMBER: NIHRID6160.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/jnnp-2014-307672

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 103

Metadata

Authors
Lu, C.-H., Petzold, A., Topping, J., Allen, K., Macdonald-Wallis, C., Clarke, J., Pearce, N., Kuhle, J., Giovannoni, G., Fratta, P., Sidle, K., Fish, M., Orrell, R., Howard, R., Greensmith, L., & Malaspina, A.
Venue
Journal of Neurology, Neurosurgery & Psychiatry
Publisher
BMJ
Published
2014-07-09
Volume
86
Issue
5
Pages
565-573
ISSN
  • 0022-3050 (ISSN-L)
  • 1468-330X
OpenAlex
W2158562257
Cited by
103
References
5
FWCI
5.63
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study. https://app.cochat.ai/papers/10.1136/jnnp-2014-307672
The paper
Lu, C.-H., Petzold, A., Topping, J., Allen, K., Macdonald-Wallis, C., Clarke, J., Pearce, N., Kuhle, J., Giovannoni, G., Fratta, P., Sidle, K., Fish, M., Orrell, R., Howard, R., Greensmith, L., & Malaspina, A. (2015). Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study. Journal of Neurology, Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp-2014-307672

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.